Trials / Completed
CompletedNCT00334139
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 411 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Bisphosphonates have been used extensively in the treatment and the prevention of skeletal complications associated with bone metastases in patients with breast cancer and prostate cancer. The purpose of this study is to assess the effect of zoledronic acid patients with prostate cancer or breast cancer and bone metastasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoledronic Acid | every 4 weeks for 4 months |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2006-06-06
- Last updated
- 2017-02-07
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00334139. Inclusion in this directory is not an endorsement.